Trial Profile
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects With Moderately to Severely Active Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Upadacitinib (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms SELECT-EARLY
- Sponsors AbbVie; AbbVie Germany
- 15 Nov 2023 Results (n=945) reporting safety and efficacy through five years from OTE portion of this trial presented at the ACR Convergence 2023
- 12 Jun 2023 Results of post-hoc pooled analysis of 6 studies (NCT02706873, NCT02675426, NCT02629159, NCT02706951, NCT02706847 and NCT03086343) assessing potential risk of upadacitinib in a similar RA population, published in the Annals of the Rheumatic Diseases.
- 03 Jun 2023 Results of a post-hoc pooled analysis from six SELECT programs assessing impact of baseline ASCVD risk on the incidence of MACE with upadacitinib versus TNFi and MTX in an RA population presented at the 24th Annual Congress of the European League Against Rheumatism